Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 18/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668442 | 0.91 | OGA (0.56) | OGA | |
| SCHEMBL20281964 | 0.88 | SMN1; SMN2 (0.74) | OGASMN1; SMN2 | |
| SCHEMBL16113448 | 0.86 | SMN1; SMN2 (0.76) | OGASMN1; SMN2 | |
| SCHEMBL27099904 | 0.85 | OGA (0.65) | OGASMN1; SMN2 | |
| SCHEMBL18992532 | 0.84 | OGA (0.67) | OGA | |
| SCHEMBL20268599 | 0.83 | OGA (0.65) | OGA | |
| SCHEMBL20586843 | 0.83 | OGA (0.67) | OGA | |
| SCHEMBL16114197 | 0.83 | OGA (0.67) | OGA | |
| SCHEMBL27022375 | 0.83 | OGA (0.74) | OGA | |
| SCHEMBL22079715 | 0.82 | SMN1; SMN2 (0.48) | OGASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | OGA 1/4885SMN1; SMN2 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.